GT Biopharma
GTBP
35 hedge funds and large institutions have $1.11M invested in GT Biopharma in 2023 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 4 closing their positions.
0% more funds holding
Funds holding: 35 → 35 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
0.26% less ownership
Funds ownership: 0.56% → 0.3% (-0.26%)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
63% less capital invested
Capital invested by funds: $3.05M → $1.11M (-$1.93M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$48.3K |
| 2 |
Millennium Management
New York
|
+$31.8K |
| 3 |
Renaissance Technologies
New York
|
+$7.88K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$7.34K |
| 5 |
MCG
McCollum Christoferson Group
Amherst,
New York
|
+$6.04K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.21M |
| 2 |
BlackRock
New York
|
-$24.3K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$20.4K |
| 4 |
Jane Street
New York
|
-$10.4K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$9.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| $2K | +$446 | +43 | +51% |
|
27
UBS Group
Zurich,
Switzerland
| $946 | -$1.65K | -159 | -61% |
|
28
JP Morgan Chase
New York
| $810 | +$892 | +86 | +8,600% |
|
29
Osaic Holdings
Scottsdale,
Arizona
| $316 | – | – | – |
|
|
TF
30
TimeScale Financial
Danvers,
Massachusetts
| $171 | – | – | – |
|
|
BBPWM
31
Blue Bell Private Wealth Management
Blue Bell,
Pennsylvania
| $94 | – | – | – |
|
|
IA
32
IFP Advisors
Tampa,
Florida
| $16 | – | – | – |
|
|
RG
33
Retirement Group
San Diego,
California
| $14 | – | – | – |
|
|
AC
34
Armistice Capital
New York
| – | -$1.21M | -73,334 | Closed |
|
|
35
Citadel Advisors
Miami,
Florida
| – | -$20.4K | -1,239 | Closed |
|
|
ASN
36
Advisory Services Network
Atlanta,
Georgia
| – | -$83 | -5 | Closed |
|
37
Bank of America
Charlotte,
North Carolina
| – | -$10 | -1 | Closed |
|
|
GWSA
38
Global Wealth Strategies & Associates
Denver,
Colorado
| – | -$1 | – | – |
|
39
Simplex Trading
Chicago,
Illinois
| – | +$135 | +13 | New |
|
GTBP Hedge Fund Activity: Q2 2023 in Review
35 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q2 2023, worth a combined $1.11M — down 63% from $3.05M a quarter earlier.
Fund positioning in GTBP was balanced in Q2 2023: 4 funds opened new positions, 4 closed out, 6 added to existing stakes and 8 trimmed.
The largest buyer was Bank of Montreal, adding an estimated $48.3K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.21M sold.
- 35 institutional investors held GT Biopharma (GTBP) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $1.11M of GT Biopharma stock for Q2 2023, down 63% quarter-over-quarter.
- 4 funds opened new GT Biopharma positions in Q2 2023 and 4 closed out, a net change of 0 holders.
- The largest GT Biopharma buyer in Q2 2023 was Bank of Montreal, an estimated $48.3K added.
- The largest GT Biopharma seller in Q2 2023 was Armistice Capital, an estimated $1.21M sold.
Based on aggregated 13F filings for Q2 2023.